secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001213900-22-033756
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics CFO Blaine Davis to depart July 15, 2022
-------------------------------------------------------------

- CFO Blaine Davis leaving to pursue other opportunities, effective July 15, 2022; resignation not due to disagreements.
- Separation agreement: 12-month base salary lump sum, target bonus, COBRA and life insurance premiums, accelerated equity vesting.
- Company had $119M cash, cash equivalents and investments as of March 31, 2022, expected to fund operations into mid-2024.
- CEO Jesse Shefferman thanked Davis for building finance, commercial, and IT functions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/0001213900-22-033756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/ea161829-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-033756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer